NeoGenomics (NEO)
(Delayed Data from NSDQ)
$15.72 USD
+0.52 (3.42%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $15.72 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Cash flow Statements
Fiscal Year End for NeoGenomics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -87.97 | -144.25 | -8.35 | 4.17 | 8.01 |
Depreciation/Amortization & Depletion | 75.46 | 72.27 | 56.09 | 40.24 | 30.66 |
Net Change from Assets/Liabilities | -25.49 | -31.70 | -4.60 | -61.75 | -32.42 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 36.05 | 37.69 | -69.87 | 18.79 | 17.13 |
Net Cash From Operating Activities | -1.95 | -65.99 | -26.72 | 1.46 | 23.37 |
Property & Equipment | -28.75 | -18.79 | -64.14 | -29.10 | -20.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -419.40 | -37.00 | 0.40 |
Investments | 105.46 | 19.31 | -133.82 | -93.35 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | -15.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 76.71 | 0.52 | -632.37 | -159.44 | -19.63 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 4.62 | 12.59 | 423.21 | 147.60 | 171.98 |
Issuance (Repayment) of Debt | -0.07 | -0.76 | 331.36 | 91.31 | -11.45 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -29.29 | -3.32 | -1.06 |
Net Cash from Financing Activities | 4.55 | 11.83 | 725.29 | 235.60 | 159.47 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 79.31 | -53.65 | 66.20 | 77.62 | 163.21 |
Cash at Beginning of Period | 263.18 | 316.83 | 250.63 | 173.02 | 9.81 |
Cash at End of Period | 342.49 | 263.18 | 316.83 | 250.63 | 173.02 |
Diluted Net EPS | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 |
Fiscal Year End for NeoGenomics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -87.97 | -73.64 | -55.13 | -30.80 | -144.25 |
Depreciation/Amortization & Depletion | 75.46 | 56.38 | 37.52 | 18.55 | 72.27 |
Net Change from Assets/Liabilities | -25.49 | -29.13 | -13.41 | -1.17 | -31.70 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 36.05 | 26.66 | 16.78 | 0.73 | 37.69 |
Net Cash From Operating Activities | -1.95 | -19.74 | -14.24 | -12.69 | -65.99 |
Property & Equipment | -28.75 | -21.70 | -17.42 | -9.93 | -18.79 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 105.46 | 81.21 | 56.11 | 33.67 | 19.31 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 76.71 | 59.51 | 38.69 | 23.74 | 0.52 |
Uses of Funds
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 4.62 | 3.35 | 1.50 | 1.41 | 12.59 |
Issuance (Repayment) of Debt | -0.07 | -0.07 | -0.06 | -0.03 | -0.76 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 4.55 | 3.28 | 1.44 | 1.38 | 11.83 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 79.31 | 43.06 | 25.89 | 12.43 | -53.65 |
Cash at Beginning of Period | 263.18 | 263.18 | 263.18 | 263.18 | 316.83 |
Cash at End of Period | 342.49 | 306.24 | 289.07 | 275.61 | 263.18 |
Diluted Net EPS | -0.11 | -0.15 | -0.19 | -0.25 | -0.18 |